Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  JAMA ophthalmology

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaophthalmol.2016.0903PMID 27123562PMCID PMC4966162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

  2016cited by this paper
• The landscape of precision cancer medicine clinical trials in the United States.

  2015cited by this paper
• Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4

  2015cited by this paper
• Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses

  2014cited by this paper
• Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma

  2014cited by this paper
• Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

  2014cited by this paper
• Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.

  2014cited by this paper
• Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

  2013cited by this paper
• Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

  2013cited by this paper
• BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma

  2013cited by this paper
• Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

  2012cited by this paper
• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

  2011cited by this paper
• Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma

  2011cited by this paper
• An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.

  2010cited by this paper
• Mutations in GNA11 in uveal melanoma.

  2010cited by this paper
• Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

  2010cited by this paper
• Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

  2009cited by this paper
• Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases

  2008cited by this paper
• Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis

  2008cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• Oncogenic mutations in GNAQ occur early in uveal melanoma.

  2008cited by this paper
• Reduced expression of autotaxin predicts survival in uveal melanoma

  2007cited by this paper
• Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal Melanoma

  2007cited by this paper
• Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death

  2004cited by this paper
• Current management of uveal melanoma

  2000cited by this paper
• Clinical Ophthalmology Dovepress Dovepress Current Clinical Practice: Differential Management of Uveal Melanoma in the Era of Molecular Tumor Analyses

  year unknowncited by this paper

• Mutations with prognostic value in uveal melanoma. Analytical study of variants detected by targeted NGS.

  2026cites this paper
• Uveal Melanoma Treatment: An Update.

  2026cites this paper
• Nanobiotechnology‐Based Approaches for Uveal Melanoma Treatment

  2026cites this paper
• BAP1 loss impairs Non-Homologous End Joining DNA repair promoting genomic instability

  2026cites this paper
• Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.

  2026cites this paper
• Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis

  2025cites this paper
• Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease

  2025cites this paper
• The Small Choroidal Melanoma: Diagnosis, Treatment Outcomes, and Unending Controversy

  2025cites this paper
• Real-World Outcomes of Ipilimumab–Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study

  2025cites this paper
• Histopathological characteristics of secondary enucleation after iodide-125 plaque radiotherapy in Chinese patients with uveal melanoma

  2025cites this paper
• Aqueous humor biomarkers in ocular oncology: Insights and advances

  2025cites this paper
• A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma

  2025cites this paper
• Non-Cutaneous Melanoma: Biology, Clinical Management, Current Therapy, and Future Directions in Treatment.

  2025cites this paper
• Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement

  2025cites this paper
• Comprehensive Genomic Profiles of Melanoma in Veterans Compared to Reference Databases.

  2025cites this paper
• Higher AJCC stage at primary tumor diagnosis may predict shorter survival in metastatic uveal melanoma

  2025cites this paper
• Identification of two distinct uveal melanoma subtypes based on the immune cell infiltration of the primary tumour

  2025cites this paper
• Ephrin Receptors and Ephrin Ligands in Uveal Melanoma: A Big Data Analysis Using Web Resources

  2025cites this paper
• Early Genetic Evolution of Driver Mutations in Uveal Melanoma

  2025cites this paper
• Early genetic evolution of driver mutations in uveal melanoma

  2025cites this paper
• Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma

  2025cites this paper
• A rare case of choroidal melanoma in pregnant Indian female

  2024cites this paper
• New immunotherapy approaches as the most effective treatment for uveal melanoma.

  2024cites this paper
• Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma

  2024cites this paper
• Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis

  2024cites this paper
• A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways

  2024cites this paper
• From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

  2024cites this paper
• Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress

  2024cites this paper
• Heterogeneity and molecular landscape of melanoma: implications for targeted therapy

  2024cites this paper
• The role of circulating tumor DNA in melanomas of the uveal tract

  2024cites this paper
• Survival Benefit of Primary Tumor Treatment in Uveal Melanoma: A Re-Analysis of the Collaborative Ocular Melanoma Study (COMS) and Natural History Study (NHS) Cohorts

  2024cites this paper
• Comparative phosphoproteome analysis of primary and metastatic uveal melanoma cell lines

  2024cites this paper
• A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets.

  2024cites this paper
• Clonal determinants of organotropism and survival in metastatic uveal melanoma

  2024cites this paper
• COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING

  2024cites this paper
• The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome

  2024cites this paper
• Uveal melanoma: molecular-genetic mechanisms of arising and the therapeutic approaches

  2024cites this paper
• Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches

  2024cites this paper
• Updates in the Management of Uveal Melanoma.

  2024cites this paper
• Malignant blue melanoma.

  2024cites this paper
• Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

  2024cites this paper
• Stereotactic radiotherapy for uveal melanoma: A case report.

  2024cites this paper
• Pathological and Molecular Diagnosis of Uveal Melanoma

  2024influential citation
• Identification of targetable epigenetic vulnerabilities for uveal melanoma

  2024cites this paper
• 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)

  2024cites this paper
• GNAQ/GNA11-Related Benign and Malignant Entities—A Common Histoembriologic Origin or a Tissue-Dependent Coincidence

  2024cites this paper
• Uveal melanoma modeling in mice and zebrafish.

  2023cites this paper
• Clinicopathological features, current status, and progress of primary central nervous system melanoma diagnosis and treatment

  2023cites this paper
• Expanded detection and impact of BAP1 alterations in cancer

  2023cites this paper
• Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis

  2023cites this paper
• Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas

  2023cites this paper
• Cutaneous melanoma.

  2023cites this paper
• Promotor methylation in ocular surface squamous neoplasia development: epigenetics implications in molecular diagnosis

  2023cites this paper
• Analysis of Recurrent DNA Base Pair Mismatches in Eye Cancer Patient Genomes

  2023cites this paper
• A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma

  2023cites this paper
• Clinical features and treatment outcomes of progressive uveal melanoma

  2023cites this paper
• Large extraocular extension of a choroidal melanoma with orbital inflammation

  2023cites this paper
• Next-generation sequencing of a large uveal melanoma with whole genome doubling and a PBRM1 mutation

  2023cites this paper
• Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond

  2023cites this paper
• Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.

  2023cites this paper
• Genetics and RNA Regulation of Uveal Melanoma

  2023cites this paper
• Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data

  2023cites this paper
• Molecular profiling of primary uveal melanoma: results of a Polish cohort

  2023cites this paper
• Advances in the clinical management of uveal melanoma

  2023cites this paper
• Tumor Profiles of Late Presentation Uveal Ring Melanoma With Novel Characteristics – A Case Series

  2023cites this paper
• The Genomic Landscape of Melanoma and Its Therapeutic Implications

  2023cites this paper
• Correlation between BAP1 Localization, Driver Mutations, and Patient Survival in Uveal Melanoma

  2022cites this paper
• TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM

  2022cites this paper
• Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling

  2022cites this paper
• FOXD1 Is a Transcription Factor Important for Uveal Melanocyte Development and Associated with High-Risk Uveal Melanoma

  2022cites this paper
• Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases

  2022cites this paper
• New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma.

  2022cites this paper
• Integrative analysis identifies key genes related to metastasis and a robust gene-based prognostic signature in uveal melanoma

  2022cites this paper
• Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma

  2022cites this paper
• GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma

  2022cites this paper
• Intrinsic Disorder in BAP1 and Its Association with Uveal Melanoma

  2022cites this paper
• Pervasive conditional selection of driver mutations and modular epistasis networks in cancer

  2022cites this paper
• Solitary Metastases Presentation from Uveal Melanoma: Report of 3 Cases and a Comprehensive Review of the Literature

  2022cites this paper
• Targeted Therapy for Melanomas Without BRAF V600 Mutation

  2022cites this paper
• Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma: Long-Term Survival in Metastatic Ciliochoroidal Melanoma.

  2022cites this paper
• SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma

  2022cites this paper
• The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989

  2022cites this paper
• Liver metastasis in uveal melanoma - treatment options and clinical outcome.

  2022cites this paper
• Uveal Melanoma – Standardised Procedure in Diagnosis, Therapy and Surveillance Das uveale Melanom – standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge

  2021cites this paper
• The Sex Differences in Uveal Melanoma: Potential Roles of EIF1AX, Immune Response and Redox Regulation

  2021cites this paper
• The AMP‐dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma

  2021cites this paper
• Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part I: MR imaging with pathologic correlation and technical considerations

  2021cites this paper
• The epidemiology of uveal melanoma in Germany: a nationwide report of incidence and survival between 2009 and 2015

  2021cites this paper
• Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma

  2021cites this paper
• Small High-Risk Uveal Melanomas Have a Lower Mortality Rate

  2021cites this paper
• Luteolin inhibits the proliferation, adhesion, migration and invasion of choroidal melanoma cells in vitro.

  2021cites this paper
• Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients

  2021cites this paper
• UVEAL MELANOMA IN A 15-YEAR-OLD GIRL. CASE REPORT.

  2021cites this paper
• Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort

  2021cites this paper
• Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions

  2021cites this paper
• Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

  2021cites this paper
• Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.

  2021cites this paper
• Applying Single-Cell Technology in Uveal Melanomas: Current Trends and Perspectives for Improving Uveal Melanoma Metastasis Surveillance and Tumor Profiling

  2021cites this paper
• Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma

  2021cites this paper
• PTK2 Promotes Uveal Melanoma Metastasis by Activating Epithelial-to-Mesenchymal Transition

  2021cites this paper